Outcomes after Pancreatectomy with Routine Pasireotide Use John W. Kunstman, MD, Debra A. Goldman, MS, Mithat Gönen, PhD, Vinod P. Balachandran, MD, FACS, Michael I. D'Angelica, MD, FACS, T Peter Kingham, MD, FACS, William R. Jarnagin, MD, FACS, Peter J. Allen, MD, FACS Journal of the American College of Surgeons Volume 228, Issue 2, Pages 161-170.e2 (February 2019) DOI: 10.1016/j.jamcollsurg.2018.10.018 Copyright © 2018 American College of Surgeons Terms and Conditions
Figure 1 Incidence of the primary end point (aggregate incidence of pancreatic fistula/leak/abscess) in the current study population routinely receiving pasireotide vs the control population that received placebo. Error bars indicate 95% CI. Journal of the American College of Surgeons 2019 228, 161-170.e2DOI: (10.1016/j.jamcollsurg.2018.10.018) Copyright © 2018 American College of Surgeons Terms and Conditions
eFigure 1 Schematic of study design noting enrollment and randomization from earlier controlled trial evaluating pasireotide in patients undergoing pancreatectomy17 compared with the current study, as indicated. Journal of the American College of Surgeons 2019 228, 161-170.e2DOI: (10.1016/j.jamcollsurg.2018.10.018) Copyright © 2018 American College of Surgeons Terms and Conditions